ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2415

Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network

Nehad Soloman1, Jawad Bilal2, Romy Cabacungan3, Scott Milligan4, Andrew Sharobeem5, John Tesser6 and Henry Leher7, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2University of Arizona, Tucson, AZ, 3Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, 4Trio Health, Louisville, CO, 5AARA, Peoria, AZ, 6Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 7Aurinia Pharma, Stowe, VT

Meeting: ACR Convergence 2024

Keywords: Disease Activity, Lupus nephritis, population studies, practice guidelines, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in subsets based upon demographic or other factors. In this study of patients with SLE in care of community rheumatologists, we identified a population with suspected LN based upon ICD codes and indicators of kidney impairment.

Methods: A retrospective analysis of the American Rheumatology Network (ARN) electronic medical records database included patients with ≥2 diagnosis codes for SLE and an observation window of at least 365 days between July 2018 and June 2023. Individual patient observation windows were calculated from the first date of observation by ARN i.e. the index date. Suspected LN criteria included a qualifying events of (1) ICD 10 codes for lupus nephritis, (2) ICD codes indicative of kidney conditions such as nephrotic/nephritic syndrome, hematuria, proteinuria, chronic kidney disease, and end-staged kidney disease, (3) eGFR decrease ≥20% occurring >30 days past initial measure and ≤72 ml/min/1.73m2, and/or (4) evidence of proteinuria by a) protein test strip 3+ or higher, b) protein in urine >14 mg/dL (or >150mg/day), and/or c) UPCR >0.5 mg/mg.

Results: A total of 8631 patients were included in the study. [FIGURE] Overall, 62% (5314/8631) of patients were identified as having suspected LN; 40% (2106/5314) with ICD 10 LN code; 26% (1394/5314) had an ICD 10 code associated with kidney conditions; 43% (2266/5314) had eGFR decrease events; 48% (2528/5314) had proteinuria. The study population was 91% female and 50% White race; 50% of patients were at least 50 years of age at the index date. Demographics of the study population and cohorts are provided in the TABLE.

Conclusion: This study provides real world descriptive demographic information characterizing patients with lupus receiving treatment in a community setting. Nearly two-thirds of patients had ICD 10 coding or clinical laboratory measures suggestive of renal involvement. Regular screening for proteinuria and hematuria via urinalysis may result in earlier detection and intervention to minimize long term renal organ damage.

Supporting image 1

FIGURE: Study Population Funnel and Cohorts

Supporting image 2

TABLE: Demographics of Study Population


Disclosures: N. Soloman: AbbVie/Abbott, 6, Amgen, 6, AstraZeneca, 6, aurinia, 2, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 2, UCB, 6; J. Bilal: None; R. Cabacungan: None; S. Milligan: AstraZeneca, 5, Aurinia, 5, Scipher, 5; A. Sharobeem: Abbvie, 6, Exagen, 6, Scipher, 6; J. Tesser: Abbvie, 2, 5, 6, Alpine, 5, Amgen, 2, 6, AnaptysBio, 5, Aqtual, 5, AstraZeneca, 2, 5, 6, Aurinia, 6, Bendcare, 6, Biogen, 5, 6, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 5, 6, Celgene, 5, Corevitas, 5, CSL Behring, 5, Eli Lilly, 2, 5, 6, Genentech, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, 6, Horizon, 5, IGMBiosciences, 5, Janssen, 2, 5, 6, KolonTissueGene, 5, Novartis, 2, Organogenesis, 5, Pfizer, 5, 6, Sanofi/Genzyme, 2, 5, 6, Setpoint, 5, UCB, 2, 5; H. Leher: Aurinia Pharma, 3.

To cite this abstract in AMA style:

Soloman N, Bilal J, Cabacungan R, Milligan S, Sharobeem A, Tesser J, Leher H. Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characterizing-the-population-with-suspected-lupus-nephritis-in-care-of-a-community-rheumatology-network/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-the-population-with-suspected-lupus-nephritis-in-care-of-a-community-rheumatology-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology